AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00209495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin; Dexamethasone
Description: Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
Study NCT00209495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin; Dexamethasone
Description: Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
Study NCT01799213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg po QD
Description: Eligible subjects will be take Meloxicam 15 mg po QD
Study NCT01799213 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks
Study NCT01116765 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no stimulation of the oral structure
Study NCT01116765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stimulation of the oral structure
Study NCT02941822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Description: Details outlines in the intervention description.
Study NCT05182983 — intervention group
Intervention type: OTHER
Intervention: Tongue images，coating on the tongue and clinical data
Description: Take photos of the tongue of patients with gastrointestinal diseases and collect clinical information.
Study NCT02476851 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: POLFA (Needle Assembly)
Description: Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
Study NCT03564496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS Administration during MRI
Description: All participants including healthy controls and MS patients will be given approximately 15 minutes of active tDCS during MRI. The simultaneous tDCS will be performed up to 2 mA dose intensity to determine CMRO2 changes from when the tDCS is on to when the tDCS is off. The stimulation consists of 15-min up to 2 mA tDCS using 5x5 cm electrode sponges with \~30s ramp-up and ramp-down periods.
Study NCT03564496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remotely-supervised Daily tDCS Administration
Description: While the first tDCS session will be performed at clinic under the full supervision, remaining sessions 2-20 (\~ 1 month) will be completed at home with remote monitoring by the study technician. Participants in the HC subgroup who opt-in to the additional 15 minutes of imaging +tDCS may complete the first session remotely.~For at-home tDCS administration, participants will be given the specially-designed tDCS device and headset, study laptop computer for secure video monitoring with study technician (must have internet access) and access to the cognitive training program, a detailed reference manual, and a training video. The device will produce up to 2.0 mA stimulation for around 20 minutes, and will not operate without the correct headset placement. The device will also automatically abort the session if optimal conditions are not maintained. It reports and records a completion code for each session.
Study NCT03564496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remotely-supervised Daily tDCS Administration
Description: While the first tDCS session will be performed at clinic under the full supervision, remaining sessions 2-20 (\~ 1 month) will be completed at home with remote monitoring by the study technician. Participants in the HC subgroup who opt-in to the additional 15 minutes of imaging +tDCS may complete the first session remotely.~For at-home tDCS administration, participants will be given the specially-designed tDCS device and headset, study laptop computer for secure video monitoring with study technician (must have internet access) and access to the cognitive training program, a detailed reference manual, and a training video. The device will produce up to 2.0 mA stimulation for around 20 minutes, and will not operate without the correct headset placement. The device will also automatically abort the session if optimal conditions are not maintained. It reports and records a completion code for each session.
Study NCT03564496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA
Description: Participants in the healthy control subgroup who are willing may have an additional 15 minutes of imaging combined with 10 minutes of simultaneous tDCS of up to 4.0mA added at the end of their baseline scan. In this case, after the initial imaging and tDCS portion is complete, the participant will remain on the scanner for an additional 15 minutes during which brain imaging will continue and will be combined with 10 minutes of simultaneous tDCS up to 4.0mA. This will be a one-time add-on and will not be required at follow-up.
Study NCT03660319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Music Therapy
Description: Experiencing Environmental Music Therapy during wait time in radiation oncology waiting room.
Study NCT02816346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)
Study NCT04271930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Awareness Practices for Insomnia
Description: MAP-I is a curriculum-based intervention that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
Study NCT04271930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Health Information
Description: A video SHE seminar will serve as active comparator for nonspecific treatment elements that pose rival explanations for the effectiveness of MAP-I.
Study NCT02476851 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Kawasumi (Needle Assembly)
Description: Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
Study NCT00921219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
Study NCT03491319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group X - head low tilt
Description: spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal anaesthesia
Study NCT03491319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Y - head low tilt
Description: the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
Study NCT03491319 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group C - neutral
Description: spinal anaesthesia was given with table in neutral positon. Patient was maintained in supine position for 10 minutes following spinal anaesthesia
Study NCT01825915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Hysterectomy
Study NCT01825915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Supracervical Hysterectomy
Study NCT03964220 — intervention group
Intervention type: DRUG
Intervention: Tiotropium Respimat®
Description: Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )
Study NCT03964220 — intervention group
Intervention type: DRUG
Intervention: Inhaled Corticosteroid/Long-acting beta-agonist
Description: baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
Study NCT06520267 — intervention group
Intervention type: DRUG
Intervention: Antibiotic therapy
Description: Urine culture and antibiotic sensitivity tests were conducted to assess the bacteriological profile. The patients were then prescribed antibiotics based on susceptibility testing for a duration of 1 week.
Study NCT01346657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifidipine & LipoCol
Description: The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
Study NCT04247854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus subtilis probiotic
Description: Bacillus probiotic which contains one confidential ingredient of Bacillus subtilis spores (2 x 1010 CFU/g). Over 5 days of interventional period, the patient receives one tablet (250 mg; 5 x 109 CFU) of probiotic per day.
Study NCT04247854 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over 5 days of interventional period, the patient receives 1 placebo tablet per day
Study NCT03102398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-399 (5% Vardenafil HCl·3H2O, topical gel)
Description: 5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
Study NCT01914302 — intervention group
Intervention type: DEVICE
Intervention: Multiclix Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances
Study NCT01914302 — intervention group
Intervention type: DEVICE
Intervention: Fastclix Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances
Study NCT01914302 — intervention group
Intervention type: DEVICE
Intervention: Reli-On Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances
Study NCT01898117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbo/cyclo
Study NCT01898117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbo/cyclo + atezolizumab
Study NCT01898117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT01898117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + Atezolizumab
Study NCT03723850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
Study NCT03723850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
Study NCT03723850 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The brain is not stimulated for 20 minutes with mild electrical current, but instead a sham procedure is administered using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
Study NCT01390012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone tablet 6 mg
Description: Dexamethasone tablet 6 mg
Study NCT01390012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection 4 mg
Description: Dexamethasone injection 4 mg
Study NCT02367651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg
Description: Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib
Study NCT02367651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets matching the 200 mg and 400 mg pazopanib tablets
Study NCT04320225 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: HD-DXM (orally at 40 mg daily for 4d )
Study NCT04282863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RM
Description: All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained. Trocar sites varied according to different procedures. Generally, umbilical site for the scope and 8-10 cm lateral to the scope at 15 degrees for the arms are the most commonly adopted sites for robotic myomectomy.
Study NCT04282863 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LM
Description: All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained: a 10 mm port is inserted through the umbilicus to introduce the video-laparoscopic system. Other three accessory 5 mm trocar are inserted into the abdomen to the left lower quadrant, right lower quadrant, suprapubic area, for operative instruments and the suction irrigator cannula.
Study NCT01524887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10% Solution
Description: Intravenous infusion every 2 weeks over 18 months
Study NCT01524887 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Human albumin 0.25%
Description: Intravenous infusion every 2 weeks over 18 months
Study NCT00378482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206 (Tremelimumab)
Description: 15 mg/kg IV every 3 months as long as required
Study NCT05682456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat shake
Description: The high-fat shake consisted of 53% (w/v) fresh cream, 3% (w/v) sugar and 44% (w/v) water
Study NCT05682456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference shake
Description: The reference shake consisted of 43% (w/v) full cream milk, 48% (w/v) full cream yoghurt, 4% (w/v) lemonade, 4% (w/v) fantomalt (Nutricia B.V., the Netherlands) and 1% (w/v) wheat fiber
Study NCT04752852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg/2 ml dexamethasone IV, 60 minutes before the induction of anaesthesia
Study NCT01998035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RomiDEPsin 10 MG/M2
Description: Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10 mg/m2)
Study NCT01998035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 5-Azacitidine 100 MG
Description: A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100 mg)
Study NCT01998035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin 14 MG/M2
Description: Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (14 mg/m2)
Study NCT01998035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 5-Azacitidine 200 MG
Description: A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (200 mg)
Study NCT01998035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 5-Azacitidine 300 MG
Description: A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (300 mg)
Study NCT03411122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: napabucasin
Description: Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.
Study NCT03411122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate
Description: CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.
Study NCT02343822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Injection
Description: Plasma component of blood rich in growth factors~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing
Study NCT02343822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Injection
Description: Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing
Study NCT02343822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Injection
Description: Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing
Study NCT04212741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A+ HA(tm)
Description: oral solution of hyaluronic acid mixture
Study NCT04212741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution with no-active ingredients
Study NCT03823339 — intervention group
Intervention type: DRUG
Intervention: Insulin degludec/liraglutide
Description: Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.
Study NCT04283929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention 1 (Int1)
Description: This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.
Study NCT00418756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
Study NCT00362427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC
Description: 0.5 mL, 4 doses, IM
Study NCT00362427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC
Description: 0.5 Ml, 4 doses, IM
Study NCT00362427 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC
Description: 0.5 mL, 4 doses, IM with concommitant vaccines
Study NCT04283929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention 2 (Int2)
Description: The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.
Study NCT04283929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention 3 (Int3)
Description: The data on VL results in the EMR showing detectable virus will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for at least 12 months and the VL result in the EMR shows > 1000 copies/mm3. The alert will be displayed on the patient summary and on the consult sheets requesting actions to address treatment failure (change first line medication, start second line medication, repeat VL, counselling on treatment adherence). A report will also be added to regularly check for patients with high viral load.
Study NCT04532697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncaria Rhynchophylla (Gou-Teng)
Description: Uncaria Rhynchophylla (Gou-Teng) is a kind of Chinese Medicine. All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
Study NCT04752852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
Study NCT01033903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 800 micrograms intravaginally ONCE
Study NCT05888363 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Difference in outcomes in patients with rectal foreign bodies removed in the emergency department or in the operating room.
Study NCT02446197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Directed Exercise Group
Description: Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
Study NCT02689726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTL001+
Study NCT02597439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Study NCT02597439 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02689726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldara
Description: 5% imiquimod cream